Health Care Supplies

Arch Therapeutics, Inc.

Arch Therapeutics, Inc. released FY2021 Q4 earnings on December 17, 2021 (EST), actual revenue 1.565 K USD (forecast 945 K USD), actual EPS -1.4887 (forecast -2)

Lavoro

Brand Engagement Network

Datavault AI

Polyrizon

TRAILBLAZER MERGER CORP I USD0.0001 CL A (S/R21/04/2028)

Sky Quarry

Hyperscale Data

ParaZero Tech

Atlantic

AgEagle Aerial

Essilor

HOYA Corporation

Align

Merit Medical

UFP Tech

Acme Utd

Xtant Med

STANDARD DENTAL LABS INC

Alcon

Cooper Cos

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Arch Therapeutics, Inc.(ARTH.US)